While many cancer types have added new treatments including genetically targeted drugs and immunotherapies, treatment for the rare types of cancer known as sarcomas have remained largely the same for about two decades. Now, two grants to University of Colorado Cancer Center researchers from the Sarcoma Foundation of America hope to change this.
Cancer Center | 
June 22, 2020
OncLive
August 25, 2020
Erin Schenk, MD, PhD, University of Colorado Cancer Center member, discusses the rapidly evolving treatment landscape in lung cancer.
OncLive
August 18, 2020
Paul A. Bunn, Jr, MD, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado, and a 2014 Giant of Cancer Care® in Lung Cancer, discusses potentially targeting HER3 in non–small cell lung cancer (NSCLC).
Oncology Learning Network
August 10, 2020
“Current guidelines recommend a 28-day course of enoxaparin for thromboprophylaxis after surgery for gynecologic cancer,” wrote Saketh R. Guntupalli, Director of the Division of Gynecologic Oncology, University of Colorado School of Medicine, and colleagues.
OncLive
July 27, 2020
Paul A. Bunn, Jr, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado and a 2014 Giant of Cancer Care® in Lung Cancer, highlights encouraging data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutant non–small cell lung cancer (NSCLC).
